China-based Venus Medtech (Hangzhou) Inc., (HKG: 2500), has entered into a strategic partnership with Valgen Holding Corporation concerning Valgen’s DragonFly transcatheter mitral valve clamp system (DF). The financial terms of the agreement have not been disclosed.
Commercial Collaboration and Market Expansion
Upon obtaining market approval for the DragonFly system, the two companies plan to engage in an extensive commercial collaboration. Valgen intends to leverage Venus Medtech’s extensive market sales network, which encompasses nearly 500 Class3A hospitals, to broaden its market reach. Additionally, Valgen will make use of Venus’s comprehensive market access channels and robust clinical technology training system to enhance the product’s market penetration and clinical adoption.- Flcube.com
